Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Mertens

Showing results (101-110 of 211) with videos related to

Pageof 22
Sort By:
European Urology Oncology|April 16, 2025
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST ProjectAlexandra Masson-Lecomte, Guillaume Grisay, Julien Van Damme, et al.
International Journal of Surgical Pathology|April 25, 2022
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory AnalysisLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Minerva Urology and Nephrology|June 14, 2023
Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomyDavid D'Andrea, Shahrokh F Shariat, Francesco Soria, et al.
Journal of Clinical Medicine|April 13, 2024
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder CancerRenate Pichler, Johannes Stäblein, Andrea Mari, et al.
Medicina (Kaunas, Lithuania)|May 27, 2023
The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder CancerFrancesco Claps, Giulio Rossin, Bas W G van Rhijn, et al.
Annals of the Rheumatic Diseases|September 7, 2018
Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndromeLucas L van den Hoogen, Joël A G van Roon, Jorre S Mertens, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 23, 2018
Prostate sparing cystectomy for bladder cancer: A two-center studyCharlotte S Voskuilen, Elisabeth E Fransen van de Putte, Jose I Pérez-Reggeti, et al.
World Journal of Urology|September 3, 2025
Routine annual imaging does not aid in diagnosing new functional complications more than five years after RC with ileal conduitJoanneke B Ringia, Femke E F Scholte, Renee A G Lijnen, et al.
European Urology Oncology|July 27, 2025
FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial CarcinomaRenate Pichler, Nils C H van Creij, Laura S Mertens, et al.
Actas Urologicas Espanolas|February 15, 2025
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic diseaseR Pichler, N C H van Creij, J D Subiela, et al.
Pageof 22

Showing results (101-110 of 211) with videos related to

Sort By:
Pageof 22
European Urology Oncology|April 16, 2025
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST ProjectAlexandra Masson-Lecomte, Guillaume Grisay, Julien Van Damme, et al.
International Journal of Surgical Pathology|April 25, 2022
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory AnalysisLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Minerva Urology and Nephrology|June 14, 2023
Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomyDavid D'Andrea, Shahrokh F Shariat, Francesco Soria, et al.
Journal of Clinical Medicine|April 13, 2024
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder CancerRenate Pichler, Johannes Stäblein, Andrea Mari, et al.
Medicina (Kaunas, Lithuania)|May 27, 2023
The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder CancerFrancesco Claps, Giulio Rossin, Bas W G van Rhijn, et al.
Annals of the Rheumatic Diseases|September 7, 2018
Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndromeLucas L van den Hoogen, Joël A G van Roon, Jorre S Mertens, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 23, 2018
Prostate sparing cystectomy for bladder cancer: A two-center studyCharlotte S Voskuilen, Elisabeth E Fransen van de Putte, Jose I Pérez-Reggeti, et al.
World Journal of Urology|September 3, 2025
Routine annual imaging does not aid in diagnosing new functional complications more than five years after RC with ileal conduitJoanneke B Ringia, Femke E F Scholte, Renee A G Lijnen, et al.
European Urology Oncology|July 27, 2025
FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial CarcinomaRenate Pichler, Nils C H van Creij, Laura S Mertens, et al.
Actas Urologicas Espanolas|February 15, 2025
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic diseaseR Pichler, N C H van Creij, J D Subiela, et al.
Pageof 22